Swisscom profit drops 23% as Vodafone Italia costs weigh on results
Investing.com - H.C. Wainwright has lowered its price target on FibroBiologics (NASDAQ:FBLG) to $5.00 from $10.00 while maintaining a Buy rating on the stock, citing investor reservation ahead of clinical progress. The new target still represents significant upside from FBLG’s current price of $0.33, with analyst targets ranging from $4 to $15. InvestingPro data shows the stock is trading near its 52-week low of $0.32.
The firm noted that FibroBiologics plans to initiate a Phase 1/2 trial for its fibroblast-based spheroids candidate CYWC628 for diabetic foot ulcers during the first quarter of 2026, with completion expected in the third quarter of 2026.
H.C. Wainwright highlighted that FBLG shares have declined over 80% year-to-date, compared to the Nasdaq Biotechnology Index’s 20% gain during the same period, as investors await further clinical validation. InvestingPro data confirms this steep decline, showing a precise 83.65% YTD drop and a 89.94% fall over the past year. The company’s market capitalization has shrunk to just $13.7 million.
The company continues to make progress on manufacturing preparation for CYWC628, with manufacturing training runs and sterility confirmation expected by the end of 2025, in compliance with FDA current Good Manufacturing Practice standards. Investors should note that FibroBiologics’ financial health is rated as "WEAK" by InvestingPro, with a current ratio of 0.78 indicating short-term obligations exceed liquid assets.
FibroBiologics is also advancing preclinical IND-enabling studies for its psoriasis treatment candidate CYPS317 and multiple sclerosis treatment CYMS101, with H.C. Wainwright’s price target reduction reflecting updated share count and tempered estimates for diabetic foot ulcer treatment adoption. The company reported an EBITDA of -$17.55 million in the last twelve months and is scheduled to report earnings in 2 days, on November 7, 2025.
In other recent news, FibroBiologics has announced significant advancements in its Bone Marrow Organoid platform. The company reported that pre-IND animal trials demonstrated a notable reduction in tumor size when their proprietary organoids were transplanted into a xenografted melanoma mouse model. This technology also facilitates efficient ex vivo gene editing for targeted therapeutic interventions. Additionally, FibroBiologics is making strides with its fibroblast spheroid technology aimed at treating chronic-relapse psoriasis. Positive updates in this area were highlighted by H.C. Wainwright, which maintained a Buy rating and a $10 price target on the company’s stock. The research firm noted the progress in pilot studies to advance preclinical development. These developments could potentially offer new treatment options for hematopoietic cancers and age-related immune decline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.